Validation of the modified hemagglutination inhibition assay (mHAI), a robust and sensitive serological test for analysis of influenza virus-specific immune response

Journal of Clinical Virology

Volumn 56, Issue 4, 2013, Pages 323-330

  Morokutti, A ^a,c   Redlberger Fritz, M ^b   Nakowitsch, S ^a   Krenn, B M ^a   Wressnigg, N ^a   Jungbauer, A ^c   Romanova, J ^a   Muster, T ^a   Popow Kraupp, T ^b   Ferko, B ^a  

^a Avir Green Hills Biotechnology AG   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

Bioassay validation; GxP analysis; ICH guideline; Immunogenicity; Influenza serology; Vaccine efficacy effectiveness

Indexed keywords

BOVINE SERUM ALBUMIN; INFLUENZA VACCINE; VIRUS ANTIGEN;

ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; NONHUMAN; PRIORITY JOURNAL; SEROLOGY;

ANIMALS; ANTIBODIES, VIRAL; ERYTHROCYTES; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; ORTHOMYXOVIRIDAE INFECTIONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN, BOVINE; VIRAL LOAD;

EID: 84875117960     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.12.002     Document Type: Article

References (56)

1. Storch G.A. Diagnostic virology. Clin Infect Dis 2000, 31(3):739-751.
2. Baumgarten A. Viral immunodiagnosis. Yale J Biol Med 1980, 53(1):71-83.
3. Hierholzer J.C., Suggs M.T., Hall E.C. Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation. Appl Microbiol 1969, 18(5):824-833.
4. Gamblin S.J., Skehel J.J. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 2010, 285(37):28403-28409.
5. Stevens J., Donis R.O. Influenza virus hemagglutinin-structural studies and their implications for the development of therapeutic approaches. Infect Disord Drug Targets 2007, 7(4):329-335.
6. Skehel J.J., Wiley D.C. Influenza haemagglutinin. Vaccine 2002, 20(Suppl. 2):S51-S54.
7. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69:531-569.
8. Weis W., Brown J.H., Cusack S., Paulson J.C., Skehel J.J., Wiley D.C. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 1988, 333(6172):426-431.
9. Wiley D.C., Skehel J.J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987, 56:365-394.
10. Hirst G.K. The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J Exp Med 1942, 75(1):49-64.
11. Salk J.E. A simplified procedure for titrating hemagglutinating capacity of influenza-virus and the corresponding antibody. J Immunol 1944, 49(2):87-98.
12. Ogra P.L., Chow T., Beutner K.R., Rubi E., Strussenberg J., DeMello S., et al. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. J Infect Dis 1977, 135(4):499-506.
13. Wagner R., Matrosovich M., Klenk H.-D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 2002, 12(3):159-166.
14. Air G.M. Influenza neuraminidase. Influenza Other Respi Viruses 2011, 6(4):245-256.
15. Lin Y.P., Gregory V., Collins P., Kloess J., Wharton S., Cattle N., et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?. J Virol 2010, 84(13):6769-6781.
16. Chen A., Poh S.L., Dietzsch C., Roethl E., Yan M.L., Ng S.K. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells. BMC Biotechnol 2011, 11:81.
17. He C., Yang Z., Tong K. Downstream processing of Vero cell-derived human influenza A virus (H1N1) grown in serum-free medium. J Chromatogr A 2011, 1218(31):5279-5285.
18. Woolcock P.R. Avian influenza virus isolation and propagation in chicken eggs. Methods Mol Biol 2008, 436:35-46.
19. World Health Organisation (WHO) Manual for the laboratory diagnosis and virological surveillance of influenza 2011.
20. Allwinn R., Preiser W., Rabenau H., Buxbaum S., Sturmer M., Doerr H.W. Laboratory diagnosis of influenza-virology or serology?. Med Microbiol Immunol 2002, 191(3-4):157-160.
21. Petric M., Comanor L., Petti Cathy A. Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics. J Infect Dis 2006, 194(Suppl. 2):S98-S110.
22. Rothbarth P.H., Groen J., Bohnen A.M., de Groot R., Osterhaus A.D. Influenza virus serology-a comparative study. J Virol Methods 1999, 78(1-2):163-169.
23. Beyer W.E.P., Palache A.M., Lüchters G., Nauta J., Osterhaus A.D.M.E. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res 2004, 103(1-2):125-132.
24. Zakay-Rones Z. Human influenza vaccines and assessment of immunogenicity. Expert Rev Vaccines 2010, 9(12):1423-1439.
25. Mancini G., Donatelli I., Arangio-Ruiz G., Rozera C., Macchia T. Comparison of haemagglutination-inhibition and single radial haemolysis techniques for detecting antibodies to influenza A and B viruses. J Hyg (Lond) 1983, 91(1):157-162.
26. Ndifon W., Dushoff J., Levin S.A. On the use of hemagglutination-inhibition for influenza surveillance: surveillance data are predictive of influenza vaccine effectiveness. Vaccine 2009, 27(18):2447-2452.
27. Cai Z., Zhang T., Wan X.F. Antigenic distance measurements for seasonal influenza vaccine selection. Vaccine 2011, 30(2):448-453.
28. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(5937):197-201.
29. Barakat A., Benjouad A., Manuguerra J.C., El Aouad R., Van der Werf S. Virological surveillance in Africa can contribute to early detection of new genetic and antigenic lineages of influenza viruses. J Infect Dev Ctries 2011, 5(4):270-277.
30. European Medicines Agency (EMA). Harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96); 1997.
31. Nauta J.J., Beyer W.E., Osterhaus A.D. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals 2009, 37(4):216-221.
32. Noah D.L., Hill H., Hines D., White E.L., Wolff M.C. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol 2009, 16(4):558-566.
33. Wood J.M., Gaines-Das R.E., Taylor J., Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994, 12(2):167-174.
34. Stephenson I., Das R.G., Wood J.M., Katz J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007, 25(20):4056-4063.
35. Stephenson I., Heath A., Major D., Newman R.W., Hoschler K., Junzi W., et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009, 15(8):1252-1259.
36. Wood J.M., Major D., Heath A., Newman R.W., Höschler K., Stephenson I., et al. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine 2012, 30(2):210-217.
37. Wood J.M., Montomoli E., Newman R.W., Daas A., Buchheit K.H., Terao E. Collaborative study on influenza vaccine clinical trial serology. Part 2. Reproducibility study. Pharmeur Bio Sci Notes 2011, 2011(1):36-54.
38. Nakowitsch S., Wolschek M., Morokutti A., Ruthsatz T., Krenn B.M., Ferko B., et al. Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1. Vaccine 2011, 29(19):3517-3524.
39. Wressnigg N., Voss D., Wolff T., Romanova J., Ruthsatz T., Mayerhofer I., et al. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Vaccine 2009, 27(21):2851-2857.
40. Garcia-Sastre A., Egorov A., Matassov D., Brandt S., Levy D.E., Durbin J.E., et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998, 252(2):324-330.
41. Egorov A., Brandt S., Sereinig S., Romanova J., Ferko B., Katinger D., et al. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol 1998, 72(8):6437-6441.
42. Talon J., Salvatore M., O'Neill R.E., Nakaya Y., Zheng H., Muster T., et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc Natl Acad Sci U S A 2000, 97(8):4309-4314.
43. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000, 97(11):6108-6113.
44. Neumann G., Kawaoka Y. Reverse genetics of influenza virus. Virology 2001, 287(2):243-250.
45. Romanova J., Krenn B.M., Wolschek M., Ferko B., Romanovskaja-Romanko E., Morokutti A., et al. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One 2009, 4(6):e5984.
46. European Medicines Agency (EMA). ICH Q2(R1)-validation of analytical procedures: text and methodology (CPMP/ICH/381/95); 1995.
47. Ito T., Suzuki Y., Mitnaul L., Vines A., Kida H., Kawaoka Y. Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species. Virology 1997, 227(2):493-499.
48. Stephenson I., Wood J.M., Nicholson K.G., Zambon M.C. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 2003, 70(3):391-398.
49. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(4):937-943.
50. Veguilla V., Hancock K., Schiffer J., Gargiullo P., Lu X., Aranio D., et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 2011, 49(6):2210-2215.
51. Katz J.M., Hancock K., Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 2011, 9(6):669-683.
52. World Health Organisation (WHO). Recommendations for influenza vaccine composition. Available from: http://www.who.int/influenza/vaccines/vaccinerecommendations1/en/index.html.
53. Ambrose C.S., Luke C., Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi Viruses 2008, 2(6):193-202.
54. Block S.L., Yogev R., Hayden F.G., Ambrose C.S., Zeng W., Walker R.E. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008, 26(38):4940-4946.
55. Mallory R.M., Malkin E., Ambrose C.S., Bellamy T., Shi L., Yi T., et al. Safety and immunogenicity following administration of a live attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One 2010, 5(10):e13755.
56. Treanor J.J., Kotloff K., Betts R.F., Belshe R., Newman F., Iacuzio D., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999, 18:899-906.